Objective: To investigate the neuroprotective effect of ginsenoside Rb1 (GsRb1) on Parkinson's disease (PD) model mice induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) and its dose-effect relationship. Methods: Fifty C57BL/6 mice were randomly divided into five groups: control group, MPTP group, GsRb1 treatment group (low-dose group, middle dose group and high-dose group), with 10 mice in each group. The model group and the treatment group were injected MPTP (30 mg/kg) into the peritoneal cavity continuously for 5 days to prepare the PD mouse model. The treatment group received intraperitoneal injection of GsRb1 at doses of 10 mg/kg, 20 mg/kg and 40mg/kg respectively every day. The control group was given the same amount of normal saline. On the second day after administration, the behavioral changes of the mice were detected by using Rotarod test, Pole-climbing test and Grasping test. Results: Compared with the control group, the latent period of MPTP group mice was significantly reduced (P＜0.01), the climbing time was significantly increased (P＜0.01), and the Graspiing test score was significantly reduced (P＜0.01). Compared with the MPTP group, the latent period in the middle and high dose groups increased significantly (P＜0.05), the climbing time in low and middle dose groups decreased significantly (P＜0.05) and the scores of Graspiing test in middle and high dose groups were significantly higher (P＜0.05). Conclusion: GsRb1 has neuroprotective effect on MPT-induced PD model mice, and 20 mg/kg/d has a better effect.
DAI Yujing
,
SUN Jianfang
,
JIA Jianxin
,
YANG Zhanjun
,
HUO Dongsheng
. Preliminary study on neuroprotective effect of Ginsenoside Rb1 on MPTP-induced Parkinson's disease model mice[J]. Journal of Baotou Medical College, 2023
, 39(6)
: 15
-19
.
DOI: 10.16833/j.cnki.jbmc.2023.06.004
[1] Hasegawa T, Kobayashi J, Ishiyama S. Emerging disease-modifying strategies targeting α-synuclein in Parkinson's disease[J]. Brain Nerve, 2020,72(2):143-150.
[2] Church FC. Treatment options for motor and non-motor symptoms of parkinson's disease[J]. Biomolecules, 2021,11(4):612-628.
[3] Du XY, Xie XX, Liu RT. The role of α-Synuclein Oligomers in Parkinson's disease[J]. Int J Mol Sci, 2020,21(22):8645-8661.
[4] Qiao J, Zhao Y, Liu Y, et al. Neuroprotective effect of Ginsenoside Re against neurotoxininduced Parkinson's disease models via induction of Nrf2[J]. Mol Med Rep, 2022,25(6):215-228.
[5] Han Y, Wang T, Li C, et al. Ginsenoside Rg3 exerts a neuroprotective effect in rotenone-induced Parkinson's disease mice via its anti-oxidative properties[J]. Eur J Pharmacol, 2021,909(30):174413-174423.
[6] Zhang YL, Liu Y, Kang XP, et al. Ginsenoside Rb1 confers neuroprotection via promotion of glutamate transporters in a mouse model of Parkinson's disease[J]. Neuropharmacology, 2018,131(5):223-237.
[7] Jackson-Lewis V, Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease[J]. Nat Protoc, 2007,2(1):141-151.
[8] Zhang Y, He X, Meng X, et al. Regulation of glutamate transporter trafficking by Nedd4-2 in a Parkinson's disease model[J]. Cell Death Dis, 2017,8(2):2574-2586.
[9] 郝广煜, 方刚, 代玉晶, 等. 人参皂苷Rb1对H2O2诱导PC12细胞损伤的保护作用[J]. 包头医学院学报,2021,37(12):63-67.
[10] Ardah MT, Paleologou KE, Lv G, et al. Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils[J]. Neurobiol Dis, 2015,74(2):89-101.
